CAMBRIDGE, Massachusetts, USA and HEIDELBERG, GERMANY, April 2, 2024 – CATUG Inc. (CATUG) and PixelBiosciences (PixelBio), announced today a long-term strategic partnership towards providing high quality RNA materials, research tools and advanced CRO services in the field of gene editing and cell therapy. Together, CATUG, a distinguished global entity specializing in high quality messenger RNA (mRNA) and lipid nanoparticle (LNP) formulation CRDMO services, and PixelBio, a premier provider of high purity single guide RNA (sgRNA) to empower professionals engaged in gene editing research and RNA-based therapeutics development.
Driven by the shared mission and vision, both parties are excited to the dawn of the RNA therapeutic era, marked by groundbreaking technologies such as CRISPR. CRISPR's precision gene-editing capabilities, combined with the innovative strategies developed by PixelBio and CATUG, pave the way for novel treatments that could lead to the cure of many unmet medical needs, including rare genetic diseases, viral infection like HIV, cardiovascular and cancer.
Dr. Yongsheng Cheng, founder and CEO of PixelBio, expressed strong optimism and enthusiasm regarding the partnership, stating: “The CatPureTM mRNA catalog products from CATUG, characterized by its high purity and stability, ensures that therapeutic mRNA can be produced with unparalleled precision, leading to more effective and safer treatments. Coupled with the cutting-edge LNP delivery system, which optimizes cellular uptake and distribution, CATUG is setting new benchmarks for RNA therapy applications. Our internal testing with CatPureTM mRNA is mind-blowing when I see the data. This partnership represents a confluence of PixelBio's groundbreaking nMECA technology, which promises unparalleled purity and length in sgRNA synthesis, with CATUG's pioneering expertise in mRNA and LNP. Together, these entities aim to accelerate advancements in genome editing research and therapy, offering more reliable and accessible solutions for scientists and clinicians worldwide.”
Dr. Lin Jin, co-founder and CTO of CATUG, also expressed the excitement of this partnership saying, “PixelBio’s new Modality Enzyme Convergent Assembling (nMECA) platform offers a versatile, high-throughput, and cost-effective RNA product portfolio, providing solutions for various unmet synthesis needs in the market. PixelBio’s high purity customized sgRNA, paired with CATUG’s CatPureTM Cas9 mRNA have already shown supreme editing effect during internal and external potency tests. Joining force together, we are poised to provide top quality materials for mRNA technology’s applications in gene editing research and development, offering cutting-edge solutions tailored to the evolving needs of our clients.”
CATUG and PixelBio are confident that through this partnership, the two companies will pool their expertise to deliver top quality material and solutions to help advance gene editing and cell therapy industry.
About CATUG
CATUG is a specialized Contract Research and Development Manufacturing Organization (CRDMO) and a one-stop solution in nucleic acid-based therapeutics through its leading DNA, RNA, LNP, and analytical platforms. With strong expertise and know-how CATUG aims to provide customized solutions in the life cycle of mRNA therapeutics, gene editing, and gene and cell therapy development. For more detailed information, please visit https://www.catug.bio/
About PixelBiosciences
PixelBio was founded in Heidelberg, Germany. PxielBio’s proprietary technology, nMECA (new Modality Enzymatic Convergent Assembly) platform, enables enzymatic RNA synthesis with chemical modifications to protect against RNAase degradation. PixelBio provides high-throughput, cost-effective gene editing reagents (CRISPR), multiplexing in situ gene detection probes, as well as the production and research of long RNA and DNA. For more information, please visit: https://www.pixelbiosciences.com/